General Partner
- sander.van.deventer@forbion.com
- Download vCard 
Sander is General Partner and joined ABN AMRO Capital Life Sciences as venture partner in 2004. Sander is also professor of translational gastroenterology at Leiden University Medical Center and co-founder of Amsterdam Molecular Therapeutics.
Sander has also held positions on the advisory boards of the FDA and the EMEA and advised the Dutch government on e.g. the national colorectal screening program and the translational gene therapy program. Sander is the author of over 400 scientific articles, and under his supervision more than 30 students have completed their PhD thesis.
In 1995, Sander became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam, where he worked on therapeutic signal transduction inhibition, gene therapy, and (genetically engineered) probiotics. He was involved in the organization of the genomics and proteomics initiative at the University of Amsterdam. and Chairman of the Anton Meelmeijer Center for Genomics and Proteomics. From 2001 until 2004, he was chairman of the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam. Sander has been a consultant to all major Pharma and Large Biotech companies.
Sander holds Board seats at Cardoz, Amsterdam Molecular Therapeutics (IPO 2006) and Argos Therapeutics Inc. He was also on the Board of BoreanPharma (sold to Roche in 2006).
Sander was trained and board certified in internal medicine and gastroenterology, and received his medical degree and PhD from the University of Amsterdam.
Following graduation, Sander worked as a scientist at the Rockefeller University, where Tumor Necrosis Factor was discovered after which Sander was first to administer an anti-TNF antibody (registered as Remicade®) to patients with Crohn's disease. Sander studied and executed on many pre- and clinical development into immunomodulatory interventions targeting a variety of pathways by applying the broad pallet of biopharmaceutical technologies available.
Sander is chairman of the scientific advisory board of the Dutch rheumatoid arthritis foundation.
